National CineMedia, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that National CineMedia, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $15.70M | Mar 9, 2021 |
| FY2020 | Sep 24, 2020 | $6.00M | Mar 9, 2021 |
| FY2020 | Jun 25, 2020 | $4.00M | Mar 9, 2021 |
| FY2020 | Mar 26, 2020 | $64.70M | Mar 9, 2021 |
| FY2020 | Dec 26, 2019 | $147.20M | Mar 9, 2021 |
| FY2020 | Sep 26, 2019 | $110.50M | Mar 9, 2021 |
| FY2020 | Jun 27, 2019 | $110.20M | Mar 9, 2021 |
| FY2020 | Mar 28, 2019 | $76.90M | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $137.40M | Feb 20, 2020 |
| FY2019 | Sep 27, 2018 | $110.10M | Feb 20, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $243.20M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $240.80M | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | $165.20M | Feb 26, 2026 |
| FY2023 | Dec 29, 2022 | $249.20M | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $114.60M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $90.40M | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $444.80M | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $441.40M | Feb 20, 2020 |
| FY2019 | Dec 28, 2017 | $426.10M | Feb 20, 2020 |
| FY2018 | Dec 29, 2016 | $447.60M | Feb 22, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | ($10.60M) | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | ($22.30M) | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | $705.20M | Feb 26, 2026 |
| FY2023 | Jun 29, 2023 | $545.30M | Mar 18, 2024 |
| FY2023 | Mar 30, 2023 | ($45.50M) | Mar 18, 2024 |
| FY2023 | Dec 29, 2022 | ($28.70M) | Mar 18, 2024 |
| FY2023 | Jun 30, 2022 | ($700.0K) | Mar 18, 2024 |
| FY2023 | Mar 31, 2022 | ($25.20M) | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | ($48.70M) | Apr 13, 2023 |
| FY2020 | Dec 31, 2020 | ($35.20M) | Mar 9, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | ($13.90M) | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | ($19.50M) | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | ($27.30M) | Feb 26, 2026 |
| FY2023 | Dec 29, 2022 | $6.90M | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | ($68.60M) | Apr 13, 2023 |
| FY2020 | Dec 31, 2020 | ($20.80M) | Mar 9, 2021 |
| FY2020 | Sep 24, 2020 | ($21.30M) | Mar 9, 2021 |
| FY2020 | Jun 25, 2020 | ($23.80M) | Mar 9, 2021 |
| FY2020 | Mar 26, 2020 | $4.90M | Mar 9, 2021 |
| FY2020 | Dec 26, 2019 | $72.70M | Mar 9, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $3.10M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $3.30M | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | $3.00M | Feb 26, 2026 |
| FY2023 | Dec 29, 2022 | $4.60M | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $1.70M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $1.90M | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $3.60M | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $1.70M | Feb 20, 2020 |
| FY2019 | Dec 28, 2017 | $3.60M | Feb 20, 2020 |
| FY2018 | Dec 29, 2016 | $3.40M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $8.40M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $60.30M | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | ($6.70M) | Feb 26, 2026 |
| FY2012 | Dec 27, 2012 | $81.60M | Feb 22, 2013 |
| FY2012 | Dec 29, 2011 | $161.80M | Feb 22, 2013 |
| FY2012 | Dec 30, 2010 | $143.70M | Feb 22, 2013 |
| FY2011 | Dec 31, 2009 | $138.30M | Feb 24, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $5.60M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $5.80M | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | $3.30M | Feb 26, 2026 |
| FY2023 | Dec 29, 2022 | $2.90M | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $5.70M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $8.00M | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $14.00M | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $14.20M | Feb 20, 2020 |
| FY2019 | Dec 28, 2017 | $11.60M | Feb 20, 2020 |
| FY2018 | Dec 29, 2016 | $12.90M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $490.60M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $568.60M | Feb 26, 2026 |
| FY2024 | Dec 28, 2023 | $567.70M | Mar 6, 2025 |
| FY2023 | Dec 29, 2022 | $792.40M | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $817.40M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $886.20M | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $1.13B | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $1.14B | Feb 20, 2020 |
| FY2018 | Dec 28, 2017 | $1.17B | Feb 22, 2019 |
| FY2017 | Dec 29, 2016 | $1.14B | Mar 19, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $115.20M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $157.40M | Feb 26, 2026 |
| FY2024 | Dec 28, 2023 | $133.20M | Mar 6, 2025 |
| FY2023 | Dec 29, 2022 | $1.26B | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $1.20B | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $1.15B | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $1.25B | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $1.23B | Feb 20, 2020 |
| FY2018 | Dec 28, 2017 | $1.25B | Feb 22, 2019 |
| FY2017 | Dec 29, 2016 | $1.26B | Mar 19, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $375.40M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $411.20M | Feb 26, 2026 |
| FY2024 | Dec 28, 2023 | $434.50M | Mar 6, 2025 |
| FY2023 | Dec 29, 2022 | ($515.30M) | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | ($526.70M) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($473.10M) | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | ($379.50M) | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | ($368.00M) | Feb 20, 2020 |
| FY2018 | Dec 28, 2017 | ($362.50M) | Feb 22, 2019 |
| FY2017 | Dec 29, 2016 | ($358.20M) | Mar 19, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $500.0K | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $0 | Feb 26, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $236.40M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $280.90M | Feb 26, 2026 |
| FY2024 | Dec 28, 2023 | $316.60M | Mar 6, 2025 |
| FY2023 | Dec 29, 2022 | ($370.40M) | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | ($332.00M) | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | ($266.40M) | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | ($171.10M) | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | ($153.60M) | Feb 20, 2020 |
| FY2018 | Dec 28, 2017 | ($130.20M) | Feb 22, 2019 |
| FY2017 | Dec 29, 2016 | ($248.30M) | Mar 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $34.60M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $75.10M | Feb 26, 2026 |
| FY2024 | Dec 28, 2023 | $34.60M | Mar 6, 2025 |
| FY2023 | Dec 29, 2022 | $61.70M | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $101.20M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $180.30M | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $55.90M | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $41.40M | Feb 20, 2020 |
| FY2018 | Dec 28, 2017 | $30.20M | Feb 22, 2019 |
| FY2017 | Dec 29, 2016 | $23.00M | Mar 19, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 28, 2023 | $10.00M | Mar 18, 2024 |
| FY2023 | Dec 29, 2022 | $1.12B | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $1.10B | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $1.05B | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $926.60M | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $923.60M | Feb 20, 2020 |
| FY2018 | Dec 28, 2017 | $923.30M | Feb 22, 2019 |
| FY2015 | Dec 31, 2015 | $936.00M | Feb 26, 2016 |
| FY2014 | Jan 1, 2015 | $892.00M | Feb 27, 2015 |
| FY2013 | Dec 26, 2013 | $890.00M | Feb 21, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | 0 | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | 14 | Feb 26, 2026 |
| FY2023 | Jun 29, 2023 | 31 | Mar 18, 2024 |
| FY2023 | Mar 30, 2023 | (3) | Mar 18, 2024 |
| FY2023 | Dec 29, 2022 | (3) | Mar 18, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Mar 18, 2024 |
| FY2023 | Mar 31, 2022 | (3) | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | 0 | Apr 13, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 9, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | 0 | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | 14 | Feb 26, 2026 |
| FY2023 | Jun 29, 2023 | 31 | Mar 18, 2024 |
| FY2023 | Mar 30, 2023 | (3) | Mar 18, 2024 |
| FY2023 | Dec 29, 2022 | (3) | Mar 18, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Mar 18, 2024 |
| FY2023 | Mar 31, 2022 | (3) | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | 0 | Apr 13, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 9, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | 93.35M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | 95.76M | Feb 26, 2026 |
| FY2024 | Dec 28, 2023 | 96.84M | Mar 6, 2025 |
| FY2025 | Aug 3, 2023 | 17.41M | Feb 26, 2026 |
| FY2025 | Aug 2, 2023 | 174.11M | Feb 26, 2026 |
| FY2020 | Dec 31, 2020 | 78.04M | Mar 9, 2021 |
| FY2019 | Dec 26, 2019 | 77.57M | Feb 20, 2020 |
| FY2019 | Dec 27, 2018 | 76.98M | Feb 20, 2020 |
| FY2018 | Dec 28, 2017 | 76.24M | Feb 22, 2019 |
| FY2017 | Dec 29, 2016 | 59.87M | Mar 19, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 1, 2026 | $11.40M | Feb 26, 2026 |
| FY2025 | Dec 26, 2024 | $300.0K | Feb 26, 2026 |
| FY2025 | Dec 28, 2023 | $500.0K | Feb 26, 2026 |
| FY2023 | Dec 29, 2022 | $9.50M | Mar 18, 2024 |
| FY2022 | Dec 30, 2021 | $16.90M | Apr 13, 2023 |
| FY2021 | Dec 31, 2020 | $32.00M | Mar 3, 2022 |
| FY2020 | Dec 26, 2019 | $53.60M | Mar 9, 2021 |
| FY2019 | Dec 27, 2018 | $54.40M | Feb 20, 2020 |
| FY2019 | Dec 28, 2017 | $58.70M | Feb 20, 2020 |
| FY2018 | Dec 29, 2016 | $54.60M | Feb 22, 2019 |